Joanne Hackett

4 June 2019
BMA House, London

 

Industry expert

  Joanne Hackett

Joanne Hackett

, , Genomics England , Chief Commercial Officer

Professor Joanne Hackett is the Chief Commercial Officer at Genomics England and lead member of the Business and Investment Committee.

As CCO, Joanne is responsible for Genomics England’s industry engagement strategy by developing, managing and accelerating relationships with commercial organisations − creating opportunities for collaboration both nationally and globally.

Joanne is a clinical academic and strategic, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity, Joanne is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne's goal is to contribute in bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics.

Genomics England

The time for talking about the potential of genomic medicine is past. Genomics is not tomorrow. It’s here today. Genomics will transform patient outcomes and healthcare systems – and Genomics England is already moving to make a mainstream genomics medicine service a reality in the UK. Realising this potential fully, however, demands more as this transformation can only take place with deep industry partnerships in place. Kick starting a UK genomics industry has been a core Genomics England aim from the outset. It recognises that − whilst NHS England, Genomics England and others build the data resources, infrastructure and systems − it is industry that develops the medicines, treatments and technologies that have such a big impact on patients’ lives. Genomics is made up of many moving parts − from the understanding and consent of the public, to truly pioneering research, to building an effective clinical service. The time for talking about genomic potential is past. The time to talk to business − and forge partnership on an industrial scale – is now.

By continuing to use the site you agree to our cookies policy. Accept